undamentalytics Newsletter
Sign in

Harrow, Inc. revenue

Harrow, Inc.'s revenue was $272m in fiscal 2025, up 36.4% on the year before. Since fiscal 2013 ($10,000) it has grown at a compound 134.2% a year. Over the last twelve months it was $276m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue021020274151497289130200272276
Growth on the year before—+>999%+485.3%+105.2%+34.3%+54.5%+23.7%−4.5%+48.3%+22.2%+47.0%+53.3%+36.4%—
Gross profit0151013253434546391150204202

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Branded $196M 71.9% ▲ 68.6%
Imprimis Rx $76.5M 28.1% ▼ 8.3%
Products and services
Line of business Revenue YoY
Product Sales Net $272M ▲ 36.9%
VEVYE $88.7M ▲ 216.1%
IHEEZO $81.3M ▲ 65.0%
Other Products $25.3M ▼ 33.1%
Other Revenues $394,000 ▼ 60.4%
Other Revenue $394,000 ▼ 56.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From Harrow, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Harrow, Inc. $276m 21.1% 39.0%
Evolus, Inc. $316m 13.9% 23.4%
Aurora Cannabis Inc $232m 11.7% —
Vanda Pharmaceuticals Inc. $229m 8.1% 2.7%
Xeris Biopharma Holdings, Inc. $335m 36.3% 35.8%
Ironwood Pharmaceuticals Inc $389m 26.2% -3.1%

Compare with peers

Head to head: EOLS vs HROWACB vs HROWHROW vs VNDAHROW vs XERS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Harrow, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Harrow, Inc.